Market closed
Poseida Therapeutics/$PSTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Poseida Therapeutics
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Ticker
$PSTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
350
Website
PSTX Metrics
BasicAdvanced
$926M
Market cap
-
P/E ratio
-$0.64
EPS
0.54
Beta
-
Dividend rate
Price and volume
Market cap
$926M
Beta
0.54
52-week high
$9.45
52-week low
$1.87
Average daily volume
1.9M
Financial strength
Current ratio
3.203
Quick ratio
3.138
Long term debt to equity
87.881
Total debt to equity
94.858
Interest coverage (TTM)
-6.89%
Management effectiveness
Return on assets (TTM)
-13.11%
Return on equity (TTM)
-57.63%
Valuation
Price to revenue (TTM)
6.076
Price to book
10.61
Price to tangible book (TTM)
11.33
Price to free cash flow (TTM)
-53.519
Growth
Revenue change (TTM)
203.18%
Earnings per share change (TTM)
-57.56%
3-year earnings per share growth (CAGR)
-37.62%
What the Analysts think about PSTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Poseida Therapeutics stock.
PSTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PSTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PSTX News
AllArticlesVideos
POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX
Business Wire·2 weeks ago
Poseida shares triple on Tuesday, boosted by Roche collaboration
Invezz·2 weeks ago
Why This Gene-Therapy Company's Stock Is Rising 228%
Barrons·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Poseida Therapeutics stock?
Poseida Therapeutics (PSTX) has a market cap of $926M as of December 14, 2024.
What is the P/E ratio for Poseida Therapeutics stock?
The price to earnings (P/E) ratio for Poseida Therapeutics (PSTX) stock is 0 as of December 14, 2024.
Does Poseida Therapeutics stock pay dividends?
No, Poseida Therapeutics (PSTX) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Poseida Therapeutics dividend payment date?
Poseida Therapeutics (PSTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Poseida Therapeutics?
Poseida Therapeutics (PSTX) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.